BAMS
ECYT

Bellevue Asset Management (Switzerland)’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$401K Sell
100,000
-58,000
-37% -$267K 0.06% 118
2015
Q3 		$724K Hold
158,000
– – 0.12% 113
2015
Q2 		$820K Sell
158,000
-32,215
-17% -$193K 0.11% 115
2015
Q1 		$1.19M Buy
+190,215
New +$1.1M 0.17% 115

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s ECYT Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) reduced its Endocyte, Inc. Common Stock (ECYT) stake by 37% in Q4 2015, selling an estimated $267K and leaving 100,000 shares worth $401K. The position accounts for 0.06% of the portfolio, ranked #118.

Bellevue Asset Management (Switzerland) first reported a position in ECYT in Q1 2015 and has held it in 4 quarters since. The position peaked at $1.19M in Q1 2015. 102 funds tracked by Wall St. Rank hold ECYT as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 100,000 shares of Endocyte, Inc. Common Stock worth $401K as of Q4 2015.
  • Bellevue Asset Management (Switzerland) sold 58,000 Endocyte, Inc. Common Stock shares in Q4 2015, an estimated $267K.
  • Endocyte, Inc. Common Stock made up 0.06% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #118 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Endocyte, Inc. Common Stock in Q1 2015 and has held it in 4 quarters since.
  • Bellevue Asset Management (Switzerland)'s Endocyte, Inc. Common Stock position peaked at $1.19M in Q1 2015.
  • 102 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.